Effects of Simvastatin on the Number and Composition of ApoproteinB-Containing lipoproteins in Hypercholesterolemia

Endocrine Journal

AKIRA YAMAMOTO²  MOTOO TSUSHIMA¹  MASAAKI SUZUKI¹  YUTAKA HARANO¹  KAYOKO IKEDA RYOMOTO¹ 

[1] The Department of Atherosclerosis, Metabolism and Clinical Nutrition;Research Institute, National Cardiovascular Center

关键词: Lipoprotein composition;    HMG-CoA reductase inhibitor;    Simvastatin;    Ultracentrifugation;    ApoproteinB with highly sensitive latex method;   

DOI  :  10.1507/endocrj.43.469

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

References(33)Cited-By(4)We investigated the effects of simvastatin on the number and composition of apoproteinB (apoB)-containing lipoproteins in thirteen patients with hypercholesterolemia type IIa or IIb by measuring apoB by a highly sensitive latex method. Patients received simvastatin 5-10mg (7.7±0.7mg, mean±SEM) daily for 83-218 days (131±13 days). In both types of patients, treatment with simvastatin significantly reduced plasma cholesterol levels (mean±SEM mg/dl: in type ha from 234.4±5.4 to 171.4 ±7.8, in type IIb from 242.4±11.6 to 178.8±9.6), low density lipoprotein (LDL) cholesterol levels (from 122.6±5.2 to 68.5±4.6, and from 115.6±14.0 to 70.4±11.6 in the two types, respectively) and LDL apoB levels (from 94.5±6.6 to 60.6±7.0, and from 85.0±8.4 to 56.6±6.2, respectively). There was no significant change in cholesterol, triglyceride (TG) or apoB in very low density lipoprotein (VLDL). High density lipoprotein (HDL) cholesterol did not change in this study. With respect to lipoprotein composition, the ratio of either cholesterol or TG to apoB in VLDL, intermediate density lipoprotein (IDL) and LDL did not change significantly, but that of TG to apoB in the IDL fraction increased in type IIa. Simvastatin promotes more effective reduction in cholesterol and apoB in LDL than in VLDL, probably by increasing the hepatic LDL receptor which preferentially binds LDL.

【 授权许可】

Unknown